Thoracic organ transplantation constitutes a significant proportion of all transplant procedures. Thoracic solid organ transplantation continues to be a burgeoning field of research. This article presents a review of remarkable literature published in 2017 regarding perioperative issues pertinent to the thoracic transplant anesthesiologists.
Noteworthy Literature Published in 2017 on Lung Transplantation
The literature was searched for articles (electronic or print) involving lung transplantation (LTX) procedures published in 2017, yielding 705 articles that were narrowed down to 86 based on abstract review, and finally to 39 articles focusing on LTX. The works covered the journey of the patient from preoperative assessment, procurement of donor organs, organ preservation, the LTX procedure itself, the use of mechanical support, and the patient's postoperative course, encompassing shortand long-term outcomes. Ex vivo lung perfusion (EVLP) continues to represent one of the most exciting areas of development. In addition, other countries have had time to reflect on their outcomes following the continued widespread adoption of the lung allocation score (LAS) as a guide for organ allocation. Several large studies analyzing data from the United Network for Organ Sharing (UNOS) database examined more current outcomes in LTX and attempted to further delineate predictors of mortality and survival in LTX patients. Most studies were retrospective, with a mix of single-center and multicenter cohorts. The layout for the following sections will consist of the following: preoperative comorbidities and risk factors, organ preservation and evaluation techniques, intraoperative management and challenges, and postoperative outcomes and survival analyses. Summary of the most relevant studies on LTX published in 2017 is described in Table 1 .
Preoperative Comorbidities in Lung Transplant Recipients
Age, Sex, and Frailty. Several studies examined the relationship between recipient age and incidence of complications and mortality. A study of the idiopathic pulmonary fibrosis population demonstrated an association between age and sex with survival, where males 70 years or older had a 19% greater mortality hazard compared with females. 1 Other studies found similar relationships where increasing recipient age had a negative association with survival. [2] [3] [4] [5] An additional study found increasing age to be a significant risk factor for postoperative atrial arrhythmias and consequent increased length of stay. 6 Katsnelson et al 7 conducted a retrospective review utilizing the UNOS registry focusing on LTX patients 65 to 80 years old. Their aim was to determine whether there was a relationship between donor age and survival of older recipients. They created 2 patient groups: one where recipients received lungs from donors >10 years younger than them and a second group of recipients who received lungs from donors within 10 years of their age. Analyses demonstrated no difference in outcomes. The researchers posited that an increase in organ allocation could occur if donors who meet all donation criteria except age are reconsidered for donation with the use of a donor-recipient age matching strategy.
Recent years have brought increased awareness to the concept of frailty and its association with slower recovery times and worsening outcomes. Baldwin et al 8 predicted that in the chronic lung disease (CLD) population, there would be a higher risk for error in frailty classifications that rely on scales that focus on leisure activities. They compared the Duke Activity Status Index (DASI) to the Age of donor and recipient Sheikh et al, 1 Yeung et al, 2 Crawford et al, 3 Mulvihill et al, 4 Hayes et al 5 Association between increasing age and decreasing likelihood of survival after LTX Katsnelson et al 7 No outcome difference in recipients who received lungs from older donors closer to age of recipient Pulmonary hypertension Avriel et al 9 PAH patients with concomitant diastolic dysfunction had worse survival and greater likelihood of post-LTX ECMO support Hayes et al 5 COPD patients with preoperative PAH had a higher incidence of mortality than COPD patients without PAH Obesity and BMI Jomphe et al 12 Potential LTX recipients with BMI >30 had increased mortality if unable to decrease BMI to <30 pre-LTX Crawford et al, 3 Hayes Jr et al 5 Increasing mortality risk associated with increasing BMI Repeat LTX surgery
Hall et al 15 Decreased overall survival following LTX, higher mortality risk if age >60 at time of retransplant Schumer et al 16 No survival difference noted between single and double lung retransplant if original LTX was a double lung Organ ischemic time Chambers et al 13 Trend toward increasing ischemic times since the 1990s with no significant survival decrease Hayes Jr et al 19 Ischemic time did not have an association with outcome except when longer ischemic times were at low-volume centers DCD van Suylen et al 21 EVLP used more often in DCD cases with no decrease in survival compared to traditional DBD donors Pilarczyk et al 22 No outcome difference in DCD post-TBI donors compared to non-TBI donors EVLP Slama et al 23 No difference in outcomes of viable lungs randomized to be implanted immediately or undergo EVLP prior to implantation Yeung et al 2 Total preservation time of >12 hours for lungs that underwent EVLP was not associated with worse outcomes than lungs with <12 hours of preservation time Mechanical circulatory support Hinske et al 26 Higher mPAP >35 mm Hg and LAS >50 were strongly associated with need for mechanical support Mulvihill et al 4 Lower 6-month survival in patients who required ECMO at 72-hour postoperative time point Hoechter et al 29 Comparable outcomes in VA-ECMO versus CPB patients Blood product usage Borders et al 34 Association between massive blood transfusion in the donor and increased 30-and 90-day mortality in the recipient Björkbom et al 35 Association between intraoperative FFP use in recipients and graft failure Length of stay Crawford et al, 3 Banga et al, Minnesota Leisure Time Physical Activity questionnaire and found that in CLD patients, the DASI had a stronger association with actual physical activity levels and was more likely to identify a frail phenotype. This led to an increased predictive ability of the frail phenotype with mortality or delisting of lung transplant candidates.
Pulmonary Hypertension. Pulmonary arterial hypertension (PAH) presents a significant challenge to the anesthesiologist in LTX cases and is generally associated with worse outcomes. Appropriately, it was a recurring area of interest in the surveyed literature. Avriel et al 9 examined the interaction between diastolic dysfunction and survival in PAH patients undergoing double LTX. Diastolic dysfunction was defined as (on transthoracic echocardiography measurements) normal ejection fraction with either a reduced ageadjusted E/A ratio, increase in age-adjusted deceleration time, or increase in age-adjusted isovolumetric relaxation time. Grade 1 diastolic dysfunction was not included in their definition of diastolic dysfunction. It was observed that these patients were more likely to require extracorporeal support postoperatively and had a worse 1-year survival compared with PAH patients without diastolic dysfunction.
Salman et al 10 reviewed institutional records of patients whose primary indication for LTX was severe PAH (5% of their population). They compared the "severe PAH" group with individuals receiving a lung transplant for all other indications, including "nonsevere" PAH. All patients with severe PAH underwent bilateral LTX on veno-arterial (VA) extracorporeal membrane oxygenation (ECMO). They found no survival difference, but did observe an increased occurrence of primary graft dysfunction (PGD) at the 24-, 48-, and 72-hour marks postoperatively, along with an increased incidence of need for renal replacement therapy. The authors noted that their institutional VA-ECMO protocol may have resulted in earlier weaning of mechanical ventilation and observed comparable survival between groups despite the poor prognostic value commonly associated with PAH.
Hayes et al 5 utilized the UNOS registry to build a cohort of chronic obstructive pulmonary disease (COPD) patients with or without PAH who underwent bilateral LTX. Their primary finding was that the preoperative presence of PAH in these patients was a predictor of mortality, with a 10% increase in mortality hazard for each 10 mm Hg increase of mean pulmonary artery pressure (mPAP). Gadre et al 11 retrospectively compared outcomes in PAH patients with or without a concomitant systemic sclerosis diagnosis. No significant difference in short-or long-term survival was found between the 2 populations. There was an increased occurrence of reintubation noted in the systemic sclerosis patients. Also, the systemic sclerosis patients with PAH had a lower incidence of readmission at 1 year compared with PAH patients without systemic sclerosis.
Overall, PAH continues to represent a challenge for both the anesthesiologist and proceduralist in terms of short-and long-term outcomes. The research performed this year has indicated that the etiology of pulmonary hypertension may play a strong role in predicting outcomes.
Obesity. Increasing body mass index (BMI) is an established risk factor for several postoperative outcomes and was associated with poor outcomes following LTX in several articles. Jomphe et al 12 conducted a retrospective review of LTX patients at their institution with a focus on recipients' BMI and their BMI changes while awaiting LTX. Analyses demonstrated that patients on the wait list with a BMI >30 who did not decrease to <30 had an increased mortality risk (odds ratio [OR] 2.62) compared with the normal BMI reference group. In addition, obese patients who did not decrease their BMI to <30 demonstrated a longer time spent on mechanical ventilation and overall intensive care unit (ICU) stay compared with obese patients who reduced their BMI to <30. Among studies that performed survival analyses, there was a common trend associating increasing BMI with mortality risk in both the 30-day period 3 and overall mortality. 5 There was also a demonstrated correlation of increasing BMI with atrial arrhythmias 6 and patients on postoperative ECMO. 4 Cystic Fibrosis (CF). CF is among the most common reasons for LTX 13 and presents its own unique set of concerns and potential complications compared with other diagnoses. Hayes et al 14 utilized the UNOS database to examine the relationship between CF patient volume and LTX outcomes in CF patients. They observed a 34% lower mortality hazard for each additional 10 LTXs a center performed involving CF patients. There was no significant association between the number of overall LTXs performed involving non-CF patients and CF patient outcomes.
Retransplantation. Hall et al 15 overviewed patients who underwent repeat LTX at their institution. The repeat population trended toward higher LAS, decreased survival (1-, 3-, and 5-year time points), and had a significant trend toward increased risk of death in patients over 60 years old compared with younger patients (relative risk [RR] 10.26). The most common reason for repeat LTX was bronchiolitis obliterans syndrome followed by chronic lung allograft dysfunction.
A similar study examined the interaction between single versus double repeat LTX. 16 The authors noted that if the first LTX was a double lung, there appeared to be no difference in survival if the consequent repeat transplant was with a single or double lung. This led the authors to posit that single re-LTX instead of double may increase the donor pool without adversely affecting survival.
Organ Preservation and Donation
Donor Comorbidities. The medical comorbidities of the donor can modulate the outcomes experienced by the recipient, often regardless of organ quality. For example, donation from a cytomegalovirus (CMV)-positive donor to a CMV-negative recipient was associated with worse survival outcomes in a number of studies reviewed. 13 In addition, recipients who received lungs from diabetic donors were associated with longer length of hospital stay. 17 Single LTX recipients whose donor had diabetes also had a higher risk of 5-year mortality. 17 Organ Ischemic Time. Ischemic time for LTX has been increasing over the past 2 decades 13, 18, 19 and was a popular survival variable analyzed in the reviewed literature. The 6-hour ischemia mark has traditionally been an indicator for worse outcomes; however, recent reports regarding whether this still holds are conflicting. 20 Utilizing the International Society for Heart and Lung Transplantation (ISHLT) Registry, Chambers et al 13 noted an overall increase in lung ischemic time since the 1990s, whereas the median time was 4 hours to over 5 hours in the last decade. One possible reason offered is the increase in double LTX performed compared with single LTX, which tended to have shorter ischemic times (median 5.5 hours for bilateral and 4.2 hours for single). There was a trend toward a decrease in short-term survival that ultimately did not lead to a decrease in longterm survival. Hayes et al 19 examined the relationship between ischemic time and LTX center volume on mortality as a primary outcome. They observed no survival disadvantage in recipients with ischemic times exceeding 6 hours. However, when stratified based on center volume, there were worse outcomes observed in lowvolume centers (<15 transplants a year) for higher ischemic times.
Donation After Cardiac/Circulatory Death (DCD).
In recent years, there has been an increasing interest in DCD. Demonstration of no difference in outcomes could produce significant gains toward increasing the number of DCD organs used and improving organ allocation. van Suylen et al 21 reported results from controlled DCD versus donation after brain death (DBD) donors in a retrospective review of Dutch LTX centers. EVLP was not used in the majority (99%) of DCD lungs that went on to be transplanted. Between the 2 groups, there was no difference in the incidence of PGD or lung function at 3 months or 6 years, forced vital capacity, or survival. However, DCD donor lungs utilized for single LTX had an independent association with an increasing FEV 1 %, made worse by increasing donor age that extended to the 3-year follow-up period, compared to DBD donors.
Pilarczyk et al 22 retrospectively examined DCD experiences from their institution where the inciting event in the donor was traumatic brain injury (TBI) and noted unchanged graft and recipient survival in the short-term and 5-year post donation periods compared with non-TBI donors.
Ex Vivo Lung Perfusion. EVLP continues to be a paradigm shift in care and continues to represent a flourishing area of potential research. Several studies reported both outcomes using EVLP and further extensions of the technique with strong potential for future developments.
Slama et al 23 conducted a prospective trial that randomized accepted lungs to either undergo immediate implantation on donor center arrival or to undergo 4 hours of normothermic EVLP. There was no difference in short-or long-term clinical measures or outcomes between the groups. Yeung et al 2 queried the Toronto Lung Transplant Program database for patients with a total preservation time (combined duration of cold ischemia time and EVLP) of greater than 12 hours and compared outcomes with patients receiving lungs with <12 hours preservation time. The >12-hour group contained more lungs from DCD donors and lungs that underwent EVLP. Overall, no difference was noted between the groups with regard to ICU length of stay, incidence of graft dysfunction, or survival. These results were felt to further establish the relative safety of EVLP and the additional advantages its implementation can provide in terms of prolonged preservation times and provide an opportunity for further evaluation of donor lungs.
Animal studies displayed possible future innovations in EVLP with inhaled bronchodilator infusions during the EVLP period, demonstrating reduced PGD, 24 and the use of airway pressure release ventilation, demonstrating lower inflammatory biomarkers. 25 
Intraoperative Management, Challenges, and Concerns
Mechanical Circulatory Support (MCS). Hinske et al 26 retrospectively reviewed bilateral sequential LTX at their institution to determine any risk factors or predictors for the need for mechanical extracorporeal support during LTX. The presence of higher mPAP, higher LAS, milrinone use after intubation, and surgery via a clamshell incision were associated with the need for use of MCS. Of the predictors, the strongest association was mPAP >35 mm Hg and LAS > 50.
Mulvihill et al 4 used the UNOS registry to determine indications and outcomes of postoperative ECMO support in patients undergoing LTX. There was a trend toward postoperative ECMO use in patients with higher BMIs, pulmonary hypertension, interstitial pulmonary fibrosis, or need for preoperative ECMO. There was a lower 6-month survival noted in patients who required ECMO at the 72-hour postoperative time point (62.2%) compared with those who did not (93.8%).
MCS is in the form of cardiopulmonary bypass (CPB) or ECMO, which are often part of LTX procedures. There is no definitive conclusion regarding outcome differences in patients receiving MCS for LTX. 27, 28 The indications for mechanical support can range from patient physiologic need to the favorable operating conditions it can afford for anastomoses. 27 Hoechter et al conducted a meta-analysis examining VA-ECMO versus CPB and demonstrated comparable results between the 2 modalities with the exception of a shorter ICU stay reported in ECMO patients. 29 The meta-analysis ultimately utilized a total of 6 nonrandomized observational studies that compared ECMO and CPB. Across all the articles, 418 patients were placed on CPB and 210 were placed on ECMO. There was a nonsignificant tendency toward a lower transfusion requirement in the ECMO group and shorter ventilation times. Ultimately, there was no significant difference in mortality benefit between the 2 modalities, with the few articles reporting 1-year outcomes demonstrating 19% incidence of events in the ECMO group and 23% in the CPB group. The use of ECMO also results in significantly increased hospital charges, as explored by Hayanga et al. 30 Hospitalization charges were compared between the ECMO group, which contained patients who required ECMO at any point during their admission, and LTX patients who did not require ECMO. They stated an average hospitalization charge of $324 279.80 for LTX patients and charges of $780 391.50 for LTX patients in the ECMO group. Overall, the median length of stay for ECMO patients was 25 days versus 15 days in the non-ECMO group, with an estimated cost of $20 000/day exclusive to ECMO patients.
Protective Lung Ventilation. There has been a gradual shift toward lower tidal volumes as part of intraoperative management of most patients regardless of the presence of lung pathology. Verbeek et al 31 prospectively examined the effects of a pressure control lung ventilation strategy in patients undergoing LTX. The emphasis was on frequent recruitment maneuvers compared with a low tidal volume lung protective modality. The ventilation modalities were started once the first allograft was implanted. They found that the pressure control alveolar recruitment group had a shorter duration to extubation postoperatively and a significant improvement in PaO Intraoperative Inhaled Pulmonary Vasodilators. A series of editorials were published examining the relative utility of pulmonary inhaled vasodilators in a pro versus con format. Benefits of inhaled nitric oxide (iNO) noted were reduction in right ventricle (RV) filling pressures and possible reduction in ischemia reperfusion injury. 32 The capability of iNO to reduce ischemia reperfusion injury has come into question along with any benefit of PGD reduction. 33 Epoprostenol was noted as an alternative to iNO with the benefits of lower cost, anti-inflammatory effects, and less toxic metabolites than iNO. 32 Limitations noted for iNO were its high cost, concern for free radical-mediated lung injury, and methemoglobin production. 32 Further research in this area is required to evaluate the role of inhaled pulmonary vasodilators in LTX recipients.
Intraoperative Blood Product Transfusions and Crystalloid.
Increased attention is being paid to intraoperative blood product transfusions and possible interactions with postoperative complications and mortality. Borders et al 34 found an association between massive blood transfusion (>10 units) in the donor and increased 30-and 90-day mortality in the recipient, but no significant difference at 1 year and no difference in recipient length of stay.
The intraoperative use of fresh frozen plasma (FFP) in recipients had an association with graft failure, but red blood cells and platelets did not. 35 In addition, FFP and hydroxyethyl starch usages were found to be higher in patients who did not survive; however, postoperative usage of products did not correlate with mortality or graft failure. 35 Smith et al 36 retrospectively assessed the results from a targeted bleeding management protocol performed at their institution utilizing point of care coagulation assays. Following the implementation of the protocol, they noted a significant decrease in the frequency of all blood product transfusions except for cryoprecipitate. No differences were noted in patient outcomes or in the incidence of PGD. There was a cost difference in which blood products were $3935/patient before the protocol and $991/patient after implementation. Considering the use of intraoperative diagnostics, the total cost of laboratory protocol and blood product use were $6640/patient before implementation and $2300/patient after.
Postoperative Outcomes and Survival Analyses
Length of Stay. Length of stay both in the ICU and overall hospitalization were frequent outcome measurements that several studies addressed both directly and indirectly. Patient predictors found to be associated with prolonged hospitalization were diagnoses other than COPD, 20 pretransplant mechanical ventilation or ECMO use, 3, 20, 30 PAH, 10 history of malignancy, 20 postoperative atrial arrhythmias, and higher LAS. 20 Diagnostic predictors associated with prolonged length of stay were elevated serum creatinine, 20, 37 low serum albumin, 20 and elevated serum bilirubin. 3, 20 Procedural factors associated with prolonged length of stay were ischemic time greater than 6 hours 20 and double LTX. 20 Survival and Mortality. Massive transfusion (>10 units) in the donor trended toward increased 30-day and 90-day mortality in subsequent recipients, but not long-term. 34 Double LTX had an association with better long-term survival. 34 LTX from CMV-positive donors to CMV-negative recipients had an association with increased mortality. The use of intraoperative hydroxyethyl starch and FFP in recipients was associated with mortality in one study. 35 Vock et al 38 . No significant difference in 30-day mortality was noted between the eras (>90% in all); however, survival at 1 year was significantly improved in era 3 (84%) compared with era 1 (78%). Reassuringly, the overall survival benefit noted in the study was most evident in era 3.
Gottlieb et al 39 discuss the German experience with LTX following the implementation of an LAS-based allocation system. Following LAS implementation, they demonstrated a decrease in median waiting time (199 to 84 days), increase in 1-year survival (79.4% pre-LAS score use vs 85.8% post-LAS score use), and lower patient mortality while awaiting LTX. As would be expected, they noted a significant increase in the amount of critically ill patients receiving transplants and the percentage of patients requiring some form of mechanical support pretransplant.
Readmission. Osho et al 40 reported predictors and reasons for readmission following LTX using diagnostic codes. They found that pleural effusion was the most common reason for readmission (35.6% of cases), followed by diabetes mellitus (34.7%), atrial fibrillation (23.7%), pneumonia (23%), and shortness of breath complaints (22.2%). No comorbidities were consistent predictors of future unplanned hospitalizations. Readmission did not have a significant association with mortality, but did have an association with chronic kidney disease at 6 months. Overall, there was an unplanned readmission rate of 45.4% among all lung transplant recipients with an average cost of $200 000 .
Noteworthy Literature Published in 2017 on Cardiac Transplantation
The number of publications related to cardiac transplantation (CTX) reflects the clinical relevance of this intervention. Consequently, most of the literature reflects important areas intending to address the shortcomings in the contemporary practice of CTX. Such issues include limited availability of donor organs, assessment and modification of risk factors, and improvement of short-and long-term outcomes. Importantly, there is a continuous effort to increase the donor pool, optimize the use of available organs, adequately match donor grafts and recipient, and improve donor function. Other areas of active research include minimizing deleterious effects of immunosuppression and early diagnosis and management of organ rejection. The following section covers diverse areas expanding across the entire spectrum of perioperative care, including donor and recipient risk factors, use of MCS in CTX, donor selection and donor-recipient matching, perioperative management, and procedural risk factors. All topics were selected according to their relevance to thoracic transplant anesthesiologists and discussed in light of their impact on postoperative outcomes. Summary of the most relevant studies on CTX published in 2017 is described in Table 2 .
Preoperative Risk Factors in CTX Recipients
Amiodarone Use in Heart Transplant Recipients. There is controversy regarding whether the use of amiodarone before heart transplantation increases the risk of posttransplant morbidity and mortality. Several studies have addressed the effect of amiodarone use on postoperative outcomes after CTX. Wright et al 41 performed a retrospective review of 269 adult patients who received heart transplants at a single institution between 2010 and 2014. Multivariate analysis of this cohort found that pretransplantation amiodarone use was an independent risk factor for severe PGD (OR 6.05; 95% confidence interval [CI] 2.47-14.83; P < .001) and in-hospital mortality (OR 2.88; 95% CI 1.05-7.88; P = .039). In addition, amiodarone use had a dose-dependent effect on severe PGD.
Lushaj et al 42 analyzed 220 consecutive heart transplant recipients at a single institution (performed between January 2004 and December 2015). When comparing patients not taking amiodarone with those taking amiodarone for at least 120 days before heart transplantation, the latter group had higher incidence of PGD (4% vs 0%; P = .025) and posttransplant pneumonia (P = .047). The Amiodarone use in heart transplant recipients Wright et al, 41 Lushaj et al, 42 Rivinius et al 43 Possible association between chronic pre-CTX use of amiodarone and decreased long-term (not early) survival. Recommendations from the Conference on Donor Heart Selection from the AST. Nguyen et al 63 Patients with UNOS Status 1A and 1B benefit from a wide range of donors, including high-risk matches. UNOS status 2 patients benefit only from lowrisk donor-recipient matches. Peled et al, 65 Jalowiec et al 66 Female donor to male recipient has higher frequency of rejections and adverse events. Male donor to female recipient also has worse outcomes. Bergenfeldt et al 67 Any gender mismatch has increased mortality (regardless of BMI). In nonobese patients, weight mismatch has increased mortality. Recipient age Awad et al, 68 74 No difference in LVEF at procurement, mortality, or severe PGD between donors resuscitated after cardiac arrest vs no arrest.
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incidence of atrial fibrillation, 30-day readmission rate, and 30-day mortality were similar between both groups. Importantly, amiodarone use prior to transplant did not affect 1-year survival posttransplantation, but 5-year survival decreased (P = .03).
In another single-center retrospective study, Rivinius et al 43 stratified 530 adult patients who underwent heart transplantation between June 1989 and December 2012 and received amiodarone therapy before heart transplantation as follows: no continuous amiodarone use (during ≤90 days), acute amiodarone use (≤90 days), and chronic amiodarone use (>90 days). A total of 77.7% of patients received "no amiodarone," 17.9% had "chronic amiodarone" therapy, and 4.4% were in the "acute amiodarone" therapy group. Only patients receiving chronic amiodarone therapy had lower rates of early posttransplant atrial fibrillation (P = .0065). There was no statistically significant difference in early (30-day) or late mortality between groups. In addition, pretransplant administration of amiodarone was not related to an increased occurrence of bradycardia or requirement for permanent pacemaker implantation.
Two systematic reviews were published in 2017 on amiodarone and outcomes after heart transplantation. In a large retrospective analysis of 14 944 adult patients receiving transplants between 2008 and 2013 from the ISHLT registry, Cooper et al 44 found that patients treated with amiodarone during the pretransplant period had a 15% increased risk of mortality during the first year (hazard ratio [HR] 1.15; 95% CI 1.02-1.30; P = .03). Amiodarone use was also associated with higher incidences of cardiac reoperation, permanent pacemaker implantation, and graft failure at time of hospital discharge. Importantly, 32% of patients from this large cohort received amiodarone before CTX and amiodarone use increased with time.
Jennings et al 45 published another meta-analysis of studies (n = 16 509) through December and reported the relationship between amiodarone exposure and heart transplant outcomes. The funnel plot analysis did not suggest publication bias and the statistical heterogeneity was moderate (I 2 = 45.8%, P = .06). The authors concluded that pretransplant use of amiodarone was not associated with an increase in postoperative mortality (OR 1.38; 95% CI 0.8-2.36) versus control. In addition, longer duration of follow-up was not associated with higher odds of mortality either.
Despite some conflicting results from the studies in this field, there should be increased concern regarding pretransplantation use of amiodarone, and its use needs to be carefully evaluated in transplant candidates. Ideally, future prospective multicenter studies should be conducted to provide additional information on this important topic.
Mechanical Circulatory Support in CTX
MCS as Bridge to Heart Transplantation. Use of MCS use at the time of CTX is increasing, with more than 50% of patients presenting for first time CTX having MCS. 46 The outcomes of these patients have raised significant controversy. The need for redo-sternotomy, increased operative and CPB times, increased risk of coagulopathy and bleeding, and higher incidence of allosensitization are of particular concern. Active research is being conducted to ascertain MCS patient outcomes before transplantation. Literature published in 2016 included 2 studies that addressed this issue. Castleberry et al 47 analyzed data from 80 Lazzeri et al, 81 Chen et al, 82 Madan et al 83 Donor reduced LVEF does not negatively impact recipient outcomes and mortality.
Factor concentrates and CTX Jahangirifard et al 88 Fibrinogen concentrate decreased blood loss, red cells transfusions and reexplorations, but increased incidence of AKI. Jahangirifard et al 89 Desmopressin increases hemostasis. Enter et al 90 Four-factor PCC decreased intra-and postoperative transfusions.
Abbreviations: CTX, cardiac transplantation; IABP, intra-aortic balloon pump counterpulsation; LVAD, left ventricular assist device; BTT, bridge-to-transplant; AA, African American; BMI, body mass index; MCS, mechanical circulatory support; BiVAD, biventricular assist device; RV, right ventricle; ACR, acute cellular rejection; CAV, cardiac allograft vasculopathy; PGD, primary graft dysfunction; ECMO, extracorporeal membrane oxygenation; RVAD, right ventricular assist device; AST, American Society of Transplantation; UNOS, United Network for Organ Sharing; DCD, donation after cardiac/circulatory death; LVEF, left ventricular ejection fraction; AKI, acute kidney injury; PCC, prothrombin complex concentrate.
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transplant patients from July 2004 to December 2011 using the UNOS database. They compared outcomes between patients with intra-aortic balloon pump counterpulsation (IABP) and left ventricular assist device (LVAD) at the time of transplant. After multivariate analysis, there was no difference in early acute rejection, length of stay, or postoperative renal injury requiring dialysis. Both groups also had equivalent cumulative risk of death. Another study by Grimm et al 48 utilized UNOS data from patients who had "bridge-to-transplant" (BTT) LVAD support and underwent heart transplantation between January 2011 and December 2012 to evaluate whether duration of LVAD support influenced postoperative outcomes. After risk adjustment, duration of LVAD support did not independently predict either early mortality (from 30 days posttransplant) or late mortality (up to 1 year posttransplant). Therefore, in this study, the duration of pretransplant LVAD support did not influence posttransplant morbidity or mortality. Of high significance, a higher proportion of patients who received pretransplant support for at least 90 days were found to be functionally independent before CTX using the Karnofsky Performance Scale (≥32% versus 18%; P < .001), suggesting functional improvement during LVAD support.
LVAD Versus No LVAD Before Heart Transplantation.
A systematic review and meta-analysis developed by Seco et al 49 evaluated clinical outcomes of LVAD therapy for BTT and assessed its cost-effectiveness when comparing heart transplantation with no bridging. The analysis included clinical outcomes data from 20 different studies on 1083 patients with BTT LVAD therapy and 3492 patients who underwent heart transplantation alone. Costeffectiveness data were reported in 5 studies, including 339 patients with BTT LVAD therapy and 498 heart transplantation patients with no bridge. The meta-analysis found no difference in early (30-day) and long-term posttransplantation mortality. In a similar fashion, the study did not find differences in a set of important outcomes including bleeding, infection, stroke, renal failure, acute rejection, chronic rejection, and cardiac allograft vasculopathy (CAV). Three studies demonstrated incremental cost-effectiveness ratios below the acceptable maximum threshold. The authors suggested that LVAD BTT therapy may be cost-effective in high-risk patients and those with expected prolonged times in the waiting list. It is important to note that interpretation of cost-effectiveness analysis may be complicated by differences in health care models across different countries.
From a different perspective, another group explored the influence of BTT LVAD therapy in clinical outcomes. Jha et al 50 investigated the effect of frailty on outcomes after both BTT LVAD therapy and heart transplantation. They evaluated the preoperative presence of frailty in 100 consecutive patients between 2013 and 2016. All patients characterized as frail were reassessed at 2 months or longer postoperatively. When comparing frail with nonfrail patients, survival in frail patients was significantly lower (63 ± 10% vs 94 ± 3% at 1 year, P = .012). Frail patients also had significantly longer lengths of stay after surgical intervention for both the ICU (11 vs 5 days, P = .002) and in-hospital (49 vs 25 days, P = .003).
This study also aimed to determine whether frailty was reversible after BTT LVAD therapy and/or heart transplantation. A total of 92% of frail patients in each group improved their frailty score, after LVAD implantation (4.0 ± 0.8 to 1.4 ± 1.1, P < .001) and after heart transplant (3.2 ± 0.4 to 0.9 ± 0.9, P < .001). Although the primary objective in this study was not to compare outcomes in patients with BTT LVAD versus no bridging before heart transplant, it demonstrates that LVAD therapy can modify frailty, which could be considered a positive outcome. More important, the prospective design of the study provides additional strength to its results.
Risk Stratification of Bridge-to-Transplant (BTT) Patients.
Utilizing a different approach to address the same topic, Guha et al 51 developed a risk score to estimate outcomes after heart transplantation in patients with LVAD support as a BTT strategy. The authors used data from the UNOS database to derive developing and validation cohorts.
Risk scores were derived after risk adjustment by assigning weight to variables that independently predicted outcomes. Such variables included recipient age, African American race, recipient BMI, intravenous antibiotic use, pretransplant dialysis, and total bilirubin. The risk score significantly differentiated survival according to 3 categories: low-, moderate-, and high-risk scores in both the development and validation cohorts (P < .001). Such risk assessment scores may be useful to stratify LVAD patients before heart transplantation. Eighty-six patients from this cohort underwent CTX during the follow up period. In general, survival after HeartMate II implantation decreased as the duration of support exceeded 9 months before patients underwent transplantation. Increased mortality after transplant was also noticed when transplantation was done within 3 months of LVAD insertion. Thus, it may be best for patients to undergo transplantation between 3 and 9 months after LVAD insertion. Risk of death on LVAD was increased in patients with prior valve operation, prior coronary artery bypass graft, low albumin, low glomerular filtration rate, hypertension, and earlier date of implant. Complications during LVAD support (intracranial hemorrhage, device exchange, dialysis) are unpredictable and decrease survival.
Timing of Transplantation
Using 1998 to 2011 data from the Nationwide Inpatient Sample, Gulati et al 53 explored the impact of performing heart transplantation after left LVAD implantation during the same admission. In this cohort, 165 (7.5%) patients implanted with LVAD underwent heart transplantation during the same admission. Patients who underwent transplantation within 7 days of LVAD implantation experienced increased in-hospital mortality (26.8% vs 12.2%, P = .0483) compared with patients who underwent transplant after 8 days.
Types of MCS and Outcomes After Transplantation.
In an analysis of the Spanish national cardiac transplantation registry, Barge-Caballero et al 54 studied 291 critically ill patients who underwent heart transplantation while on temporary MCS between 2010 and 2015. Seventy-nine percent of patients underwent transplantation. Most patients (58%) were supported on VA-ECMO, while 24% and 18% were supported on temporary LVAD and biventricular assist device (BiVAD), respectively. The highest in-hospital postoperative mortality after transplantation (33%) was for patients bridged on VA-ECMO. The lowest (11.9%) was for patients on LVAD support (P = .008). The best overall survival from listing to hospital discharge was 78.6% for patients with temporary LVAD (P = .002). Use of temporary LVAD for BTT in critically ill patients was associated with better outcomes, including a lower risk of death during the first year after placement on the waiting list. Unfortunately, these results are difficult to extrapolate to countries with different allocation systems.
Another interesting study by Bartfay et al 55 describes their experience at a referral CTX center in Sweden where all patients who undergo LVAD implantation undergo transplantation due to their lack of a destination therapy program. They compared outcomes between patients who received preplanned BiVAD based on an estimated high risk of developing RV failure, with high-risk patients who received LVAD alone. The authors reported no statistically significant differences in terms of survival to heart transplantation and/or 1-or 2-year mortality. Additionally, there were no statistically significant differences in pumprelated complications or ICU and in-hospital length of stay. Based on those results, the authors suggest that preplanned BiVAD is a suitable strategy for BTT in patients at high risk for RV failure, even though patients in their BiVAD group had higher heart failure severity according to the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) classification.
HeartMate II Versus HeartWare
In another analysis of the UNOS database, Magruder et al 56 compared survival between patients undergoing BTT with HeartWare HVAD (HeartWare Inc, Miami Lakes, FL) versus HeartMate II LVAD. All adult patients who underwent BTT between January 2011 and March 2016 were included. After risk adjustment and controlling for patient, donor, and center characteristics, device selection did not predict mortality at any time point (from 30 days to up to 1 year posttransplantation).
Allosensitization in Patients
With LVAD Support Before CTX. The increased incidence of sensitization to human leukocyte antigens (HLA) or allosensitization in patients who receive LVAD before heart transplantation is of increasing concern. Allosensitization resulting from LVAD implantation has been implicated in an increased incidence of antibody-mediated rejection (AMR). Therefore, the effects of LVAD therapy on the occurrence of rejection and other post-heart transplantation outcomes, including CAV, are areas of active research. In this field, Nestorovic et al 57 evaluated the impact of LVAD implantation on the occurrence of both acute cellular rejection (ACR) and AMR. The authors retrospectively calculated both ACR and AMR scores based on the total number of rejections divided by valid biopsy samples during a 2-year period. They also correlated such scores with clinical episodes of ACR and AMR. Posttransplant outcomes analyzed included survival and occurrence of CAV. The study included 41 patients transplanted with BTT LVAD and 67 heart transplant patients with no bridging. When compared with the nonbridged patients, patients with BTT LVAD demonstrated a statistically significant increase in the number of ACR episodes. There were no differences in AMR between groups (P > .05). Despite this fact, there were no differences in survival (P > .05) or CAV.
Another study by See et al 58 found an increase in IgG polyreactive natural antibodies (non-HLA antibodies) in transplant candidates after LVAD implantation for BTT. Moreover, the levels of such antibodies were significantly increased when compared with no LVAD transplant recipients. After analysis of posttransplant clinical outcomes between groups, elevation of such pretransplant IgG antibodies was associated with development of PGD. The mechanisms of ventricular assist device-induced sensitization and its role in short-and long-term outcomes in BTT recipient patients are poorly understood and require further elucidation in the near future.
Use of MCS After Orthotopic CTX.
A significant proportion of mortality in CTX recipients occurs in the first posttransplant year. Moreover, acute graft dysfunction is the most common cause of early mortality after heart transplantation. 46 Although the first line of treatment is based on inotropic support, a proportion of patients require MCS. There is high variability in MCS choice and management strategies between institutions. It is not clear how outcomes are affected by the choice of MCS in this setting. A single center study by Tchantchaleishvili et al 59 retrospectively analyzed patients (n = 192) who received heart transplants from 2001 until 2015. MCS was required in 9.9% of their cohort. Patients who required MCS had characteristics similar to patients who did not require MCS. Although there were no differences in perioperative morbidity, the MCS group had decreased survival (at 30 days and 1 year) when compared with patients with no MCS posttransplant (94.7% vs 97.1% at 30 days, P = .01; and 61.1% vs 92.8% at 1 year, P < .001). In this cohort, 47% of patients requiring MCS were supported with right ventricular assist device (RVAD), 32% received BiVAD, and 21% had VA-ECMO. Most likely such distribution reflects the authors' preference to place BiVAD for global biventricular failure as opposed to VA-ECMO. Therefore, interpretation regarding possible outcomes of using different MCS modalities is not possible.
In a similar study, Takeda et al 60 investigated the use of MCS for patients with severe PGD at their institution. The incidence of severe PGD requiring MCS was 7.4%. Their full cohort (n = 597) consisted of patients who received heart transplants between 2007 and 2015. When comparing VAD and VA-ECMO support, there were no significant differences between groups. Also, there were no statistically significantly differences in both in-hospital mortality and 3-year posttransplant survival. More significantly, the group of patients who received VADs had higher incidences of bleeding, requiring re-exploration, and renal failure, requiring renal replacement therapy (77% vs 30%, P = .0047; and 53% vs 11%, P = .0045, respectively). Patients in the VA-ECMO support group had a higher rate of weaning from MCS support (89% vs 59%, P = .03) and short support time (5.2 ± 3.9 days vs 14 ± 17 days, P = .011). Based on these results, the authors suggest clinical outcomes may be better with the use of VA-ECMO for MCS support of severe PGD after heart transplantation. This later study reflects a larger and more contemporary cohort than the study by Tchantchaleishvili et al. 59 A systematic review by Phan et al 61 included 41 studies with 11 555 heart transplant recipients. MCS was required in 6.0%. The most common form of support was VA-ECMO, which was utilized in 79.4% of cases. The frequency of use of RVAD, BiVAD, and LVAD was 11.1%, 7.5%, and 2.0% respectively. There were no significant differences in overall pooled 30-day survival and survival to discharge between subgroups.
Donor Selection and Donor-Recipient Matching
The availability of donor organs is the main limiting factor in CTX. The number of possible organ donors has remained relatively constant during the last 20 years although recent changes in attitudes toward donation have increased the number of donors. Additional efforts have been made in expanding acceptance criteria for donation. However, despite the current acceptance of "extended donor criteria" (EDC) hearts for transplantation, there is no standard practice regarding balancing donor and recipient risk factors when selecting donors. Therefore, there is significant variability in donor acceptance practices among institutions. The recent publication of recommendations from the Conference on Donor Heart Selection from the American Society of Transplantation (AST) by Kobashigawa et al 62 represents an important advance in the standardization of donor heart selection and ultimately improving the rates of CTX. This conference established the need for a donor risk score, formal definition of EDC hearts, and modification of regulatory practices over high-risk transplantations.
Donor-Recipient Matching. The complexity of donor selection, in particular donor-recipient matching, was studied by Nguyen et al, 63 who evaluated the risk of dying or becoming too ill for transplantation while on the waiting list versus survival according to estimated donor-recipient match risk. The authors utilized the "Donor Risk Index" described by Weiss et al 64 (which includes graft ischemic time, donor age, race mismatch, and donor blood urea nitrogen/creatinine ratio) and the UNOS-assigned categories of urgency (1A, 1B, and 2 in decreasing urgency/priority). The study included 28 548 heart transplant candidates between July 2006 and December 2015. The results suggested that patients with 1A and 1B status had a significant survival benefit when considering a wide range of donor hearts, including high-risk matches. Such benefit occurred immediately for status 1A candidates and after 12 months for status 1B candidates. For status 2 candidates, there was also benefit from transplantation; however, the benefit depended on estimated donor-recipient match risk. Additionally, the benefit was evident after 3 years. The authors suggested that accepting a wide range of donorrecipient match risk should be advocated for status 1A and 1B candidates. In contrast, for status 2 candidates, matching low-risk donor hearts with low-risk recipients should be considered.
Donor-Recipient Gender Mismatch. As per the "Report from the AST Conference on Donor Heart Selection in Adult Cardiac Transplantation in the United States," 62 sex/gender mismatch between donor and recipient is an important as well as controversial risk factor in heart transplantation. More specifically, sex mismatch is particularly relevant in the setting of female to male donation. The risk carried by sex mismatch further augments when donor age increases or when donor-recipient weight ratio increases. Furthermore, in cases of increased pulmonary vascular resistance, male recipients have worse survival if they receive female donor hearts.
In this area of debate, several studies are important. Peled et al 65 analyzed diverse outcomes in a cohort of patients undergoing transplantation at a referral center in Israel between 1991 and 2013. Such outcomes were evaluated according to donor-recipient gender matching by comparing female donor-male recipient versus male donor-male recipient. The female donor to male recipient group had a significantly higher frequency of early and overall major rejections (early, 1.2 ± 1.6 vs 0.4 ± 0.8; P = .001; overall, 16 vs 5.5 per 100 person years; P < .05). This group also had higher incidence of CAV (43% vs 20%; P = .01). The male donor to male recipient group had higher probabilities of survival free of major adverse events and rejections.
In a study by Jalowiec et al, 66 of a cohort of 347 heart transplant recipients, 74% of patients received gendermismatched donor hearts. Interestingly, the group of male donor and female recipient (9.8% of the entire cohort) had more treated rejection events, more CAV, and decreased survival at 3 years.
Donor-Recipient Size Mismatch.
Using a large cohort of adult patients from the ISHLT Registry who underwent transplantation between 1994 and 2013, Bergenfeldt et al 67 explored the relationship between size matching, BMI, and gender. The study examined all-cause, 30-day, and cumulative mortality in 52 455 patients. Regardless of BMI, gender mismatch (both female donor to male recipient and male donor to female recipient) was associated with increased cumulative mortality (male recipient/ female donor, HR 1.08, 95% CI 1.04-1.12, P < .001; female recipient/male donor, HR 1.07, 95% CI 1.02-1.13, P = .003). Unlike in obese heart transplant recipients, weight mismatch in nonobese recipients was associated with increased 30-day mortality (OR 1.20, 95% CI 1.01-1.43, P = .041) and cumulative mortality (HR 1.14, 95% CI 1.07-1.22, P < .001).
Recipient Age
Considering that as per the Donor Heart Selection Conference Report:
62 "Younger donor age and good graft function should be prioritized above all other risk factors," donor age is still considered the most important risk factor to evaluate when deciding to perform heart transplantation. Nonetheless, heart transplant recipient age is also an essential risk factor to consider in heart transplantation. 62 Some available evidence shows increased incidence of specific worse outcomes in recipients >60 years old. Importantly, recipient age is considered a predictor of survival. However, evidence regarding such outcomes and survival is conflicting between single-center studies and large registry data. As a result, the upper age limit for patients considered for heart transplantation is controversial and there is important institutional variability in the maximum age for transplant candidacy. In contrast, the proportion of older patients both receiving transplants and on the waiting list continues to increase with time. Therefore, the tendency has been to increase the age limit for transplant candidacy.
Several studies continue to address such controversy by providing further evidence on outcomes in older heart transplant patients. A single-center retrospective study by Awad et al 68 analyzed a cohort of 704 adult patient who received heart transplants from December 1988 to June 2012. Patients ≥70 years old had similar early and longterm survival when compared with younger patients, even though donor heart graft ischemia time was higher in the older group (P = .002). There were no statistically significant differences in CPB time, intraoperative blood product usage, ICU and hospital length of stay, as well as rate of reoperation for bleeding, requirement of dialysis, ventilation for >48 hours, pneumonia, pneumothorax, sepsis, and in-hospital and postdischarge infections. However, more patients in the older group were UNOS status 2. The authors concluded that patients ≥70 years should not be excluded from heart transplantation candidacy based only on age.
A multicenter 20-year retrospective study of transplantation in several institutions in France by Bosseau et al 69 analyzed survival and long-term outcomes in heart transplant recipients ≥60 years of age. The analysis included 212 patients undergoing transplantation between January 1994 and December 2013. In patients ≥60 years of age, survival rates at 1, 5, and 10 years were 83.2%, 77.4%, and 63.8%, respectively. These rates are comparable to those from other published large studies and better than those for patients <60 years reported in other regions of France and Europe. Predictors of survival in multivariate analysis included ischemic cardiomyopathy and postoperative complications such as dialysis and MCS. The aforementioned contemporary studies support the concept that older patients can have optimal results and consideration for transplantation should include factors other than age.
Another study by Wever-Pinzon et al 70 evaluated the association between recipient age and cause-specific mortality in a large cohort from the ISHLT registry. A total of 52 995 transplant recipients between 1995 and 2011 were divided in groups according to age ranges. Long-term survival at 10 years was lower in heart transplant recipients in the 2 more advanced age groups: 49% for 60 to 69 years old and 36% for ≥70 years age (P < .01). The youngest recipients (18-29 years old) had a significantly higher risk of dying from acute rejection (HR 4.11; P < .01), CAV (HR 2.85; P < .01), and graft failure (HR 2.29; P < .01), suggesting a possible effect of insufficient immunosuppression. In contrast, in the oldest recipients (≥70 years old), the highest risk of death was caused by infection (HR 2.10; P < .01) and malignancy (HR 2.23; P < .01). The latter group may have been affected by over-immunosuppression. The authors suggested that treatment and management strategies should be tailored to recipient age and risk profile to improve long-term outcomes.
Because of prolonged time on the waiting list and the higher burden of comorbidities in elderly transplant recipients, the BTT strategy with LVAD is being utilized more frequently in that patient population. A study by Fukuhara et al 71 investigated outcomes in patients >70 years old to define the upper patient age limit. The authors identified 4850 heart transplant recipients who were bridged with a continuous-LVAD in the period between 2004 and 2014 using the UNOS database. When patients ≥70 years old were compared with patients 18 to 69 years old in a propensity-matched cohort, no survival difference could be demonstrated at 90 days and 3 years. Functionally independent patients showed remarkably superior posttransplant survival at 3 years (96.7% in independent patients vs 42.8% in dependent patients; P = .001).
This study provides evidence of comparable mortality of septuagenarians supported by LVAD as a BTT strategy. In this population, functional independence is an important predictor of survival and could be used for risk stratification and organ allocation.
Organ Procurement
Donation After Cardiac/Circulatory Death. The demand for organ donors in heart transplantation continues to grow. In fact, more than 4000 patients are on the waiting list in the United States. Since availability of DBD organs is limited, the utilization of DCD has been growing rapidly, mostly for abdominal transplantation. Besides ethical implications, the main methodological limitation to the use of DCD hearts is the inability to perform a functional assessment of the graft after circulatory death. The active interest in DCD for CTX has prompted studies of the functional and metabolic effects of circulatory arrest on the heart and cardiovascular system. Iyer et al 72 developed a porcine asphyxia model to describe pathophysiological changes after withdrawal of care. From care withdrawal until circulatory arrest, the mean time was 8 ± 1 minutes, and the mean time until electrical asystole was 16 ± 2 minutes. The most significant change was acute pulmonary hypertension with subsequent RV distention and decrease in left atrial volume. There was also indication of substantial myocardial release of epinephrine and norepinephrine. Such mechanistic studies support the clinical concern about the limited time after DCD before significant damage to the donor heart ensues.
Messer et al 73 reported their experience with the utilization of donor "normothermic regional perfusion" (NRP) to reestablish heart function. This procedure allows functional and hemodynamic assessment of the donor heart in situ after declaration of death and before deciding to proceed to organ procurement. After procurement, donor hearts were placed in the portable Ex-vivo Perfusion System-Organ Care System (OCS Heart, TransMedics, Inc, Andover, MA) for preservation and transport before transplantation. The authors instituted NRP in 13 adult DCD donors, 9 of which underwent organ harvesting in the clinical phase of the study. Survival of heart recipients in the clinical phase was 100%, and 2 patients required transient MCS. Furthermore, during the follow-up period (total of 1436 patient-days; range 48-297), there were no episodes of rejection. The median ICU length of stay was 5 days (interquartile range 4-5 days). In addition, the median ischemic time from withdrawal of care to reperfusion was 24 minutes (interquartile range 21-29; range 17-146 minutes). The authors also mentioned that due to using the study protocol, the transplantation rate in their center increased 45% while reducing the risk of PGD.
Using a different approach, Galeone et al 74 provide some evidence supporting the concept that a short period of warm ischemia after cardiac arrest does not necessarily have a negative effect on donor heart graft function and recipient survival after transplantation. The authors performed a retrospective review of all heart transplant recipients at their institution from July 2004 until December 2012. Heart transplantation recipients receiving grafts from donors with histories of resuscitated cardiac arrest were compared with those whose donors had no cardiac arrest. There was no difference in LV ejection fraction at procurement time between the 2 groups (62 ± 8% vs 63 ± 8%; P = .2). Despite higher troponin T peak levels in donors resuscitated after cardiac arrest, there was no difference in 30-day mortality or PGD requiring ECMO (31% vs 30%; P = .993). Ascertaining the pathophysiological, hemodynamic, and functional consequences of DCD is an evolving area of investigation. The specific mechanisms of damage in donor grafts as a consequence of DCD have not yet been elucidated. Defining the role of DCD in CTX and determining the ultimate consequences for heart transplant recipients are priorities for research and for the CTX community in general.
Cold Storage Versus Organ Care System. In another publication on utilization of the OCS, Chan et al 75 reported outcomes of patients from their institution 2 years after participation in the PROCEED II trial. 76 A single-center cohort of 38 adult patients who underwent heart transplantation between 2011 and 2013 were randomized (19 patients received donor grafts kept by standard cold storage and 19 had donor grafts preserved by the OCS). There were no significant differences between the 2 groups in a set of outcome measures including nonfatal major adverse cardiac events, clinically treated rejection, biopsy-proven ACR or AMR, freedom for CAV and mortality (survival at 2 years: OCS, 72.2%; cold storage, 81.6%; P = .38). When compared with the cold ischemia group, the OCS group had a shorter cold ischemia time (134 ± 45 minutes vs 207 ± 50 minutes; P < .001) and a significantly longer total ischemia time (361 ± 96 minutes vs 207 ± 50 minutes; P < .001). At the author's institution, OCS preservation at 2 years had outcomes comparable to standard cold storage. More important, OCS effectively decreased the cold ischemic time in the donor grafts. OCS may be used for organ preservation and transportation, offering an alternative to traditional methods. Reporting and assessment of longterm outcomes is necessary to further define the role of OCS preservation in contemporary heart transplantation.
Donor Comorbidities and Other Risk Factors
Comorbidities other than donor age and gender were also investigated as the determinants of outcomes after heart transplantation. Donor hypertension 77 has been shown to affect survival, and prolonged QTc interval >500 milliseconds 78 have been shown accelerate the development of CAV. Hyperglycemia, 79 reduced LV function, [80] [81] [82] [83] and longer distance between donor and recipient hospital 84 have been studied recently and have not been shown to affect outcomes.
Perioperative Management
Vasoplegia During the Perioperative Period. Patients who undergo heart transplantation are at risk of developing vasoplegia. More important, increasing evidence shows that the presence of vasoplegia in this setting carries a poor prognosis. The specific risk factors and mechanisms leading to vasoplegia in heart transplant recipient patients are being investigated. A single-center retrospective review of 347 consecutive patients by Chan et al 85 revealed that the presence of long-term MCS at transplant time was associated with vasoplegia syndrome (30.8% vs 20% in patients with no MCS, P = .039) within 48 hours of heart transplantation. Additionally, patients with vasoplegia had an increased length of stay and duration of mechanical ventilation. However, mortality at 1 year and rates of rejection were similar between both groups.
Another single-center retrospective review of cases performed at Columbia University between 2012 and 2015 86 revealed that according to their definition, the incidence of vasoplegia during CPB in this cohort was 16%. Of significance in this study, patients with vasoplegia had increased mortality at both 30 and 60 days. Another important finding included that bridging to heart transplantation with continuous flow LVAD was an independent predictor of vasoplegia during CPB. Other risk factors included higher BMI and recipient male gender. It is important to note that the definitions of vasoplegia, and in particular, timeframes for its occurrence, differed between these 2 studies (within 48 hours vs during CPB only). Notably, and despite differences between studies, the presence of long-term MCS was an independent predictor of vasoplegia in both studies. Further studies are required to identify risk factors and to elucidate the role of vasoplegia in outcomes for heart transplant recipients.
Sugammadex in Post-Heart Transplant Patients. Varela et al 87 reported a patient who underwent left upper lobectomy 10 years after heart transplantation. The patient previously suffered cardiac arrest secondary to administration of neostigmine. Since sugammadex does not influence cholinergic system, this drug was used safely for reversal of rocuronium blockade in this patient. The authors recommended further research in this area.
Factor Concentrates and Heart Transplantation. Jahangirifard et al 88 studied the hemostatic effect and morbidity in 23 CTX patients receiving fibrinogen 2 g after termination of CPB and heparin reversal and compared with controls who did not receive fibrinogen. Fibrinogen infusion decreased postoperative blood loss, red cell transfusions in the first 24 hours, and re-explorations after CTX but increased the incidence of acute kidney injury. The same group also demonstrated hemostatic efficacy of desmopressin in CTX patients. 89 Enter et al 90 compared 21 CTX patients receiving 4-factor (PCC) with 39 CTX patients who did not receive PCC. PCC reduced preoperative transfusion by 46%, intraoperative transfusion of red blood cells by a median of 4 units, and FFP by a median of 5 units. Blood transfusion in the first 48 hours was also reduced by 27% in PCC group compared to controls. The efficacy and safety of factor concentrates in CTX recipients should be explored in future randomized clinical trials.
Conclusions
In this review, we highlighted the relevant literature published in 2017 regarding thoracic organ transplantations. Published areas of interest for anesthesiologists include preoperative donor and recipient risk factor identification, modification of those risk factors, optimization of recipient condition before transplantation, exploration of better organ protective strategies, and few interesting concepts in perioperative management.
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